Cerebrolysin in Alzheimer's disease: a randomized, double-blind, placebo-controlled trial with a neurotrophic agent

[1]  S. Kasper,et al.  A 28-week, double-blind, placebo-controlled study with Cerebrolysin in patients with mild to moderate Alzheimer's disease , 2001, International clinical psychopharmacology.

[2]  B. Oh,et al.  A Double‐Blind, Placebo‐Controlled, Multicenter Study of Cerebrolysin for Alzheimer's Disease , 2000, Journal of the American Geriatrics Society.

[3]  S. Gauthier,et al.  Acetylcholinesterase inhibitors in the treatment of Alzheimer's disease. , 1999, Expert opinion on investigational drugs.

[4]  S. Gauthier,et al.  Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. , 1999, The American journal of occupational therapy : official publication of the American Occupational Therapy Association.

[5]  Dafang Wu,et al.  In vivo upregulation of the blood–brain barrier GLUT1 glucose transporter by brain-derived peptides , 1999, Neuroscience Research.

[6]  E. Masliah,et al.  Cerebrolysin Ameliorates Performance Deficits, and Neuronal Damage in Apolipoprotein E-Deficient Mice , 1999, Pharmacology Biochemistry and Behavior.

[7]  R. Mohs,et al.  A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease , 1998, Neurology.

[8]  R. Hayes,et al.  Nerve Growth Factor Attenuates Cholinergic Deficits Following Traumatic Brain Injury in Rats , 1997, Experimental Neurology.

[9]  Karyn M. Frick,et al.  The Effects of Nerve Growth Factor on Spatial Recent Memory in Aged Rats Persist after Discontinuation of Treatment , 1997, The Journal of Neuroscience.

[10]  V. Valoušková,et al.  Nerve growth factor and nootropic drug Cerebrolysin but not fibroblast growth factor can reduce spatial memory impairment elicited by fimbria-fornix transection: short-term study , 1996, Neuroscience Letters.

[11]  B. Winblad,et al.  Intracranial infusion of purified nerve growth factor to an Alzheimer patient: The first attempt of a possible future treatment strategy , 1993, Behavioural Brain Research.

[12]  J. Cedarbaum,et al.  The Therapeutic Potential of Neurotrophic Factors in the Treatment of Parkinson's Disease , 1993, Experimental Neurology.

[13]  T. Sato,et al.  Neurotrophic factor-like effect of FPF1070 on septal cholinergic neurons after transections of fimbria-fornix in the rat brain. , 1992, Histology and histopathology.

[14]  Z. Khachaturian.  Editorial: The five-five, ten-ten plan for Alzheimer's disease , 1992, Neurobiology of Aging.

[15]  R. Nitsch,et al.  Nerve growth factor and choline acetyltransferase activity levels in the rat brain following experimental impairment of cerebral glucose and energy metabolism , 1992, Journal of neuroscience research.

[16]  F. Hefti,et al.  Effect of recombinant human nerve growth factor on presynaptic cholinergic function in rat hippocampal slices following partial septohippocampal lesions: Measures of [3H]acetylcholine synthesis, [3H]acetylcholine release and choline acetyltransferase activity , 1991, Neuroscience.

[17]  E. Alleva,et al.  NGF and cholinergic control of behavior: anticipation and enhancement of scopolamine effects in neonatal mice. , 1991, Brain research. Developmental brain research.

[18]  H. C. Moises,et al.  Exogenous NGF Affects Cholinergic Transmitter Function and Y-Maze Behavior in Aged Fischer 344 Male Rats , 1991, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[19]  F. Gage,et al.  NGF improves spatial memory in aged rodents as a function of age , 1991, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[20]  L. Williams,et al.  Hypophagia is induced by intracerebroventricular administration of nerve growth factor , 1991, Experimental Neurology.

[21]  D. Price,et al.  Recombinant human nerve growth factor prevents retrograde degeneration of axotomized basal forebrain cholinergic neurons in the rat , 1991, Experimental Neurology.

[22]  P. Erhart,et al.  Die Brauchbarkeit der ereigniskorrelierten Negativität zum Nachweis therapeutischer Wirkungen von Nootropika am Beispiel von Cerebrolysin , 1990 .

[23]  P. Erhart,et al.  A multidimensional approach in testing nootropic drug effects (Cerebrolysin). , 1990, Archives of gerontology and geriatrics.

[24]  L. Olson,et al.  Rescue of basal forebrain cholinergic neurons after implantation of genetically modified cells producing recombinant NGF , 1990, Journal of neuroscience research.

[25]  J. Conner,et al.  Nerve growth factor (NGF) reverses axotomy-induced decreases in choline acetyltransferase, NGF receptor and size of medial septum cholinergic neurons , 1989, Brain Research.

[26]  G. Alexopoulos,et al.  Cornell scale for depression in dementia , 1988, Biological Psychiatry.

[27]  S H Ferris,et al.  Behavioral symptoms in Alzheimer's disease: phenomenology and treatment. , 1987, The Journal of clinical psychiatry.

[28]  B. Will,et al.  Long-term effects of nerve growth factor and neural transplants on behavior of rats with medial septal lesions , 1986, Brain Research.

[29]  K. Davis,et al.  A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.

[30]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[31]  R. Katzman.,et al.  Pathological verification of ischemic score in differentiation of dementias , 1980, Annals of neurology.

[32]  S. Folstein,et al.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. , 1975, Journal of psychiatric research.

[33]  M. Lawton,et al.  Assessment of Older People: Self-Maintaining and Instrumental Activities of Daily Living , 1969 .

[34]  M. Windisch,et al.  Two Peptidergic Drugs Increase the Synaptophysin Immunoreactivity in Brains of 24-month-old Rats , 2004, The Histochemical Journal.

[35]  Y. Heqin,et al.  Efficacy of FPF 1070 (Cerebrolysin) in Patients with Alzheimer’s Disease , 2000 .

[36]  V. Valoušková,et al.  Can Cerebrolysin influence chronic deterioration of spatial learning and memory? , 1998, Journal of neural transmission. Supplementum.

[37]  M. Windisch,et al.  The influence of Cerebrolysin and E021 on spatial navigation of 24-month-old rats. , 1998, Journal of neural transmission. Supplementum.

[38]  F. Hefti.  Neurotrophic Factor Therapy of Alzheimer’s Disease , 1995 .

[39]  E. Rüther,et al.  Efficacy of the peptidergic nootropic drug cerebrolysin in patients with senile dementia of the Alzheimer type (SDAT). , 1994, Pharmacopsychiatry.

[40]  A. Burns.  Clinical diagnosis of Alzheimer's disease , 1991 .

[41]  G. Pepeu,et al.  Lesions of the nucleus basalis magnocellularis in the rat: morphological, biochemical and behavioral reparative effect of nerve growth factor and ganglioside GM1. , 1990, Acta neurobiologiae experimentalis.

[42]  F. Gage,et al.  Potential use of neurotrophic agents in the treatment of neurodegenerative disorders. , 1990, Acta neurobiologiae experimentalis.